Drug Overview

ALK-FAK-PYK2 Inhibitor CT-707 (also known as Contefatinib) is an innovative medication being studied to treat specific types of lung cancer. It belongs to a group of advanced medicines called Targeted Therapy or Smart Drugs. These drugs are designed to be more precise than old-fashioned chemotherapy. Instead of attacking all fast-growing cells, CT-707 finds and blocks specific “broken” proteins that tell cancer cells to grow and spread.

Currently, CT-707 is an investigational drug. This means it is still being tested in clinical trials to ensure it is safe and works well before it can be sold at a standard pharmacy. It is primarily being developed for patients with lung cancer that has a specific genetic change.

Generic Name: Contefatinib (CT-707)
US Brand Names: None (Currently an investigational drug)
Drug Class: Tyrosine Kinase Inhibitor (TKI); ALK/FAK/PYK2 Inhibitor
Route of Administration: Oral (Tablet)
FDA Approval Status: Not yet FDA approved; currently in Phase I and Phase II clinical trials.

What Is It and How Does It Work? (Mechanism of Action)

To understand how CT-707 works, it helps to think of cancer cells as having “broken switches.” In many lung cancers, three specific switches are involved: ALK, FAK, and PYK2.

ALK (Anaplastic Lymphoma Kinase): This is a protein that can get “stuck” in the ON position. When it is stuck, it sends a constant signal to the cell to multiply and grow.
FAK (Focal Adhesion Kinase): This protein helps cancer cells move and stick to other parts of the body. It is often why cancer spreads to other organs.
PYK2: This protein works like a backup system that helps the cancer cell stay alive even when it is under attack.

How the drug stops the cancer:

CT-707 is a “triple threat” inhibitor. At the molecular level, it acts like a perfectly shaped plug that fits into the “energy pockets” (ATP-binding sites) of these three proteins. By plugging these pockets, the drug blocks the proteins from sending growth messages.

Specifically, it shuts down signaling pathways like PI3K/AKT and MAPK/ERK. Without these messages, the cancer cell becomes confused, stops dividing, and eventually triggers a “self-destruct” sequence called apoptosis. Because it blocks three different targets at once, it is much harder for the cancer to develop a way to “hide” or become resistant to the treatment.

FDA Approved Clinical Indications

As an investigational drug, CT-707 does not have official FDA approval for general use yet. It is currently being studied for the following conditions:

Oncological Uses (Investigational):

ALK-Positive Non-Small Cell Lung Cancer (NSCLC): For patients who have never been treated before.
Resistant NSCLC: For patients whose cancer has returned after taking earlier targeted drugs like crizotinib.
Advanced Solid Tumors: General research into tumors that show high levels of FAK or ALK activity.

Non-oncological Uses:

None at this time.

Dosage and Administration Protocols

The exact dose of CT-707 is still being finalized through research. However, clinical trials have used specific daily amounts to find the balance between being effective and being safe.

Patient Type	Route	Standard Trial Dose	Frequency	Special Instructions
Adults (Phase I/II)	Oral (Tablet)	300 mg to 600 mg	Once Daily	Should be taken with a meal.
Optimized Dose	Oral (Tablet)	450 mg	Once Daily	Taken in 28-day continuous cycles.

Dose Adjustments

Hepatic (Liver) Insufficiency: Because this drug is processed by the liver, patients with liver issues may need a lower dose.
Renal (Kidney) Insufficiency: There is limited data on kidney issues; doctors monitor kidney function closely during trials.
Side Effects: If a patient develops high liver enzymes or severe stomach issues, the dose is usually lowered or paused for a few days.

Clinical Efficacy and Research Results

Recent study data from 2020–2025 has shown that CT-707 is very effective at shrinking tumors in specific groups of people.

High Response Rates: In Phase I/II trials, patients with ALK-positive lung cancer who had never taken a targeted drug before showed an Objective Response Rate (ORR) of approximately 80%. This means 8 out of 10 patients saw their tumors shrink significantly.
Stopping Progression: For patients who had already failed other treatments, the drug was able to stop the cancer from growing for a median of 13 months or longer in early reports.
Brain Metastases: Early data suggests that CT-707 may be able to reach the brain. This is very important because lung cancer often spreads there, and many older drugs cannot reach those tumors.

Safety Profile and Side Effects

Because CT-707 is a Targeted Therapy, it does not usually cause the total hair loss seen with chemotherapy. However, it does have specific side effects that doctors must watch.

Black Box Warning

There is currently no Black Box Warning for CT-707 because it is still in the testing stages.

Common Side Effects (>10%)

Gastrointestinal Issues: Nausea, vomiting, and diarrhea.
Liver Enzyme Elevation: Changes in blood tests (ALT/AST) that show the liver is under stress.
Fatigue: Feeling very tired or weak.
Creatinine Increase: A sign that the kidneys are working harder.

Serious Adverse Events

Hepatotoxicity: Serious inflammation of the liver.
Interstitial Lung Disease (ILD): Rare but serious inflammation of the lungs that can make it hard to breathe.
QT Prolongation: Changes in the electrical rhythm of the heart.

Management Strategies

For Liver Issues: Doctors perform weekly or monthly blood tests. If levels get too high, the drug is paused.
For Stomach Issues: Patients are given anti-nausea medicine and told to drink plenty of fluids to stay hydrated.
For Lung Symptoms: Any new cough or shortness of breath must be reported to the medical team immediately.

Research Areas

Current research is looking at how CT-707 works when combined with other types of treatment. Scientists are specifically interested in whether this drug can be paired with Immunotherapy. Since FAK and PYK2 (the proteins this drug blocks) are known to help cancer “hide” from the immune system, blocking them might help the immune system find and kill the cancer more effectively. There is also research into how this drug can help patients who have developed “resistance mutations” to other common lung cancer drugs.

Patient Management and Practical Recommendations

Pre-treatment Tests to be Performed

ALK Mutation Test: A biopsy or blood test (liquid biopsy) must confirm the patient has the ALK genetic change.
Liver Function Test: To ensure the liver is healthy enough to process the medicine.
Heart Check (ECG): To check the baseline rhythm of the heart.

Precautions During Treatment

Liver Monitoring: Expect to have blood drawn frequently during the first few months.
Sun Sensitivity: Some targeted drugs make skin easier to burn; wear sunscreen.

“Do’s and Don’ts”

DO take the pill at the same time every day with food.
DO tell your doctor about all other medicines you take, as some can interfere with CT-707.
DON’T stop taking the medication or change your dose without talking to your clinical trial team.
DON’T eat grapefruit or drink grapefruit juice, as it can cause the drug to build up to dangerous levels in your body.

Legal Disclaimer

This guide is for informational purposes only and does not constitute medical advice. CT-707 is an investigational drug and is not currently FDA-approved for commercial use. It should only be used under the supervision of a qualified oncologist within a clinical trial. Always consult your healthcare provider before starting any new treatment or making changes to your current care plan. The medical field moves quickly; ensure you are discussing the latest data with your oncology team.